Listed below are the charts and positions for Trikafta/Kaftrio in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Trikafta/Kaftrio.
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
NHS England has agreed a deal with Vertex for its three-drug cystic fibrosis therapy Kaftrio, just days after the EMA’s human medicines committee recommended approval of the drug. The deal means ...
Vertex Earnings: Robust Sales of Trikafta/Kaftrio Support Long-Term Growth and Diverse Pipeline Narrow-moat Vertex delivered solid third-quarter results, highlighted by a 12% increase in product ...
But when she found out about the drug Trikafta, she started thinking, “we can manage this”. Cystic fibrosis is a condition that produces thick and sticky mucus and mainly affects the lungs and ...
Hosted on MSN1mon
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product SalesTotal revenues rose 16% year over year, primarily driven by higher sales of Trikafta/Kaftrio (marketed as Kaftrio in Europe). The company currently markets four CF products, Trikafta/Kaftrio ...
“We are thrilled by the positive CHMP opinion in support of expanding the Kaftrio in combination with ivacaftor indication to include all CF patients 2 years and older who make CFTR protein,” said ...
Issuing a so-called positive opinion, EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended Kaftrio as a combination therapy for CF patients aged two years and older with a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results